Is CTBO or BTI a better dividend investment in 2026?

CTBO currently yields 198.02% with a 5% 5-year dividend growth rate. BTI yields 5.40% with 5% growth. The better choice depends on your goal: CTBO offers higher current income.

What is the dividend yield difference between CTBO and BTI?

CTBO has a forward dividend yield of 198.02% ($2.00/share annually). BTI yields 5.40% ($3.15/share annually). The yield gap is 192.62 percentage points.

Home › Compare › CTBO vs BTI

CTBO vs BTI: Dividend Comparison 2026

CTBO yields 198.02% · BTI yields 5.40%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CTBO wins by $112.66M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CTBO

● Live price

198.02%

Share price

$1.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$112.70M

Annual income

$56,534,499.65

Full CTBO calculator →

BTI

● Live price

5.40%

Share price

$58.26

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.8K

Annual income

$2,802.29

Full BTI calculator →

Portfolio growth — CTBO vs BTI

📍 CTBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CTBO	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CTBO + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CTBO pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTBO

Annual income on $10K today (after 15% tax)

$16,831.68/yr

After 10yr DRIP, annual income (after tax)

$48,054,324.70/yr

BTI

Annual income on $10K today (after 15% tax)

$459.05/yr

After 10yr DRIP, annual income (after tax)

$2,381.95/yr

At 15% tax rate, CTBO beats the other by $48,051,942.76/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTBO + BTI for your $10,000?

CTBO: 50%BTI: 50%

100% BTI50/50100% CTBO

Portfolio after 10yr

$56.37M

Annual income

$28,268,650.96/yr

Blended yield

50.15%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CTBO

No analyst data

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.3% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTBO buys

BTI buys

No recent congressional trades found for CTBO or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCTBOBTI

Forward yield	198.02% ✓	5.40%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$112.70M ✓	$37.8K
Annual income after 10y	$56,534,499.65 ✓	$2,802.29
Total dividends collected	$106.15M ✓	$14.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples

Year-by-year: CTBO vs BTI ($10,000, DRIP)

Year	CTBO Portfolio	CTBO Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$30,502	$19,801.98	$11,301	$601.08	+$19.2K → CTBO
2	$89,086	$56,448.56	$12,799	$706.58	+$76.3K → CTBO
3	$249,403	$154,080.96	$14,527	$832.38	+$234.9K → CTBO
4	$670,003	$403,142.26	$16,527	$982.75	+$653.5K → CTBO
5	$1,729,066	$1,012,162.66	$18,846	$1,162.95	+$1.71M → CTBO
6	$4,291,289	$2,441,188.37	$21,545	$1,379.49	+$4.27M → CTBO
7	$10,253,990	$5,662,310.92	$24,694	$1,640.41	+$10.23M → CTBO
8	$23,616,660	$12,644,890.45	$28,378	$1,955.69	+$23.59M → CTBO
9	$52,487,868	$27,218,041.68	$32,702	$2,337.79	+$52.46M → CTBO
10	$112,696,518	$56,534,499.65	$37,794	$2,802.29	+$112.66M → CTBO

CTBO vs BTI: Complete Analysis 2026

CTBO — Stock

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Full CTBO Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this CTBO vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTBO vs SCHD CTBO vs JEPI CTBO vs O CTBO vs KO CTBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.